Download presentation
Presentation is loading. Please wait.
1
Clinical Trials to Real World:
3
Topics of Discussion
4
Two Key Questions
5
MARINA Trial: Mean Change in VA
6
ANCHOR Trial: Mean Change in VA
7
VIEW 1/2 Trial Results: Mean Change in BCVA From Baseline to Week 52
8
Monthly Injections: The Gold Standard of Treatment
9
LUMINOUS Study: Recruitment From Third Interim Analysis
10
LUMINOUS: VA Gains in Treatment-Naive Patients Stratified by Injection Frequency Over 1 Year
11
LUMINOUS: VA Stratified by Injection Frequency and Loading Dose
12
LUMINOUS: Safety Outcomes in Treatment-Naive Patients Over 1 Year
13
AURA Study: Summary of Mean Injections and VA Scores
14
AURA Study: Mean Change in VA Score From Baseline Over Time for All Patients by Country
15
LUMIERE Study: Changes in VA
16
UNCOVER Study: Medical Coverage Categories
17
UNCOVER: Frequency of Ranibizumab Injections/Year Were Lowest in Self-Paid Category
18
Real-World Considerations Contributing to Low Injection Frequency
19
Treat-and-Extend Regimen in Real-World Clinical Practice
20
Fight Retinal Blindness Study: 12-Month Outcomes
21
CATT 5-Year Study Results: Percent of Eyes With Fluid for 552 Eyes
22
FLUID Study: Design
23
FLUID Study: Summary
24
Importance of Qualitative Assessment on Monitoring
25
Concluding Remarks
26
Abbreviations
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.